NCPA Action Alert: Weigh in Now on Pharmacy DIR Fees!
Friday, January 4, 2019
p>From NCPA: Amid a number of proposed Part D policy changes, the Centers for Medicare & Medicaid Services' recently proposed rule, Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P, features critical reform of Part D pharmacy price concessions, also known as direct and indirect remuneration or DIR fees.
Under the current system, pharmacy benefit managers – the middlemen hired by plan sponsors to administer prescription drug benefits – often claw back fees from pharmacies well after a transaction. Those fees, called direct and indirect remuneration, are often unpredictable and seemingly unconnected to a pharmacy's performance related to adherence and other standards. The fees also disadvantage patients, who are assessed a higher cost-share against their Part D deductible rather than the retroactive, lower adjusted price. The result is to push patients more quickly into the so-called Part D donut hole, at which point the patient is responsible for a considerably larger portion of their prescription drug costs.
The proposal in the rule would require all price concessions from pharmacies to be accounted for in the "negotiated" price. The only price adjustments that could be made retroactively would be additional incentive payments made to the pharmacy by the plan. The proposal will give pharmacy owners greater clarity about their reimbursement under Medicare Part D at the time a medication is dispensed.
For Part D beneficiaries, the proposal will lower the negotiated price of a medication, which will lower patients' out-of-pocket costs at the pharmacy counter for medicines purchased with a co-insurance component. That, in turn, will slow patients' progression toward the Part D donut hole, at which point the patient is responsible for a much higher percentage of prescription drug costs.
This proposal reflects the relentless work of NCPA and its pharmacy partners to bring the problem of DIR fees to the attention of policymakers. Those efforts include a succession of meetings with administration officials, legislators, and key staffers; joint stakeholder letters; and pharmacist grassroots mobilization. In fact, HHS Secretary Alex Azar and CMS Administrator Seema Verma singled out the work of community pharmacy on this issue in a joint blog post about the proposed rule, noting that "Independent pharmacies have raised concerns that back-end deals with health insurance plans are eroding competition and making it harder for them to continue providing medications to beneficiaries."
The DIR language in this proposed rule presents the best opportunity to date to address pharmacy DIR fees, and there is widespread support in the pharmacy community for it, including from retail chains and specialty pharmacies. It is vital that the pharmacy community as a whole continue to speak with a coordinated and unified voice to see that this proposal is finalized.
Use the resources below to help spread the word about the DIR provisions in the proposed drug pricing rule. And don't forget to send comments on the rule to CMS. We've made it easy via NCPA's grassroots portal.
Comment on the CMS proposal HERE.